Bowen TS, Cannon DT, Begg G, Baliga V, Witte KK, Rossiter HB. A novel cardiopulmonary exercise test protocol and criterion to determine maximal oxygen uptake in chronic heart failure. J Appl Physiol 113: 451-458, 2012. First published May 31, 2012 doi:10.1152/japplphysiol.01416.2011.-Cardiopulmonary exercise testing for peak oxygen uptake (V O2peak) can evaluate prognosis in chronic heart failure (CHF) patients, with the peak respiratory exchange ratio (RERpeak) commonly used to confirm maximal effort and maximal oxygen uptake (V O2max). We determined the precision of RERpeak in confirming V O2max, and whether a novel ramp-incremental (RI) step-exercise (SE) (RISE) test could better determine V O2max in CHF. Male CHF patients (n ϭ 24; NYHA class I-III) performed a symptom-limited RISE-95 cycle ergometer test in the format: RI (4 -18 W/min; ϳ10 min); 5 min recovery (10 W); SE (95% peak RI work rate). Patients (n ϭ 18) then performed RISE-95 tests using slow (3-8 W/min; ϳ15 min) and fast (10 -30 W/min; ϳ6 min) ramp rates. Pulmonary gas exchange was measured breath-bybreath. V O2peak was compared within patients by unpaired t-test of the highest 12 breaths during RI and SE phases to confirm V O2max and its 95% confidence limits (CI95). RERpeak was significantly influenced by ramp rate (fast, medium, slow: 1.21 Ϯ 0.1 vs. 1.15 Ϯ 0.1 vs. 1.09 Ϯ 0.1; P ϭ 0.001), unlike V O2peak (mean n ϭ 18; 14.4 Ϯ 2.6 ml·kg Ϫ1 ·min Ϫ1 ; P ϭ 0.476). Group V O2peak was similar between RI and SE (n ϭ 24; 14.5 Ϯ 3.0 vs. 14.7 Ϯ 3.1 ml·kg Ϫ1 ·min
Ϫ1

·min
Ϫ1
; P ϭ 0.476). Group V O2peak was similar between RI and SE (n ϭ 24; 14.5 Ϯ 3.0 vs. 14.7 Ϯ 3.1 ml·kg ). The RERpeak in CHF was significantly influenced by ramp rate, suggesting its use to determine maximal effort and V O2max be abandoned. In contrast, the RISE-95 test had high precision for V O2max confirmation with patient-specific CI95 (without secondary criteria), and showed that V O2max is commonly underestimated in CHF. The RISE-95 test was well tolerated by CHF patients, supporting its use for V O2max confirmation. exercise; gas exchange; peak oxygen uptake; respiratory exchange ratio EXERCISE INTOLERANCE and cardiac dysfunction characterize the syndrome of chronic heart failure (CHF). A treadmill or cycle ergometer-based peak exercise test, with noninvasive cardiopulmonary measurements for the determination of peak oxygen uptake (V O 2peak ), is the most widely used measure of physiological limitation in CHF, providing information on the degree of physiological dysfunction, symptoms, and prognosis (20) . A V O 2peak Յ 14 ml·kg Ϫ1 ·min Ϫ1 is associated with increased mortality in CHF (20) and is a key criterion in the algorithm for cardiac transplant listing (21) . Hence, accurate and reliable determination of the physiological limit of O 2 transport and utilization is crucial to guide treatment in CHF patients.
Peak exercise testing, however, is commonly symptomlimited in CHF patients due to breathlessness and fatigue. Thus many patients voluntarily terminate exercise at a V O 2peak before reaching the maximum physiological limit of O 2 delivery and utilization [V O 2max (37) ], such that the best index of aerobic capacity and integrated neuromuscular-cardiopulmonary function (29) remains underestimated. Additionally, distinguishing between the cardiopulmonary dynamics of maximal or submaximal exercise tests is extremely complex [i.e., the incidence of a plateau, or not, in the V O 2 -to-work rate relationship (9, 14) ], such that the objective data collected often do not allow a submaximal V O 2peak to be discriminated from a V O 2max . Therefore, corroborating criteria (15) from the responses of blood lactate (values Ͼ 8 mM), heart rate (to within 10% of age-predicted maximum), ratings of perceived exertion (Borg scale RPE values Ͼ 18) or the end-exercise peak respiratory exchange ratio (RER peak Ͼ 1.00 -1.15) have each been used to confirm whether 1) patients have provided a maximum effort; and 2) the measured V O 2peak is representative of V O 2max .
The utility of these secondary measures has been shown to be limited at best (15) and may even lead to a "false positive," i.e., the invalid acceptance of V O 2peak as V O 2max (30) . Nonetheless, in CHF the end-exercise RER peak has become the most commonly used secondary criterion to validate maximal effort and thus "confirm" V O 2max (12, 21, 29) , with a range of different "cut-off" values suggested: Ͼ1.00 (12); Ͼ1.05 (21); Ն1. 10 (2, 3, 22, 29) . However, interpretation of RER peak is complicated by the fact that a progressive exercise test is often delivered at a predetermined incrementation rate-a factor that interacts with the absolute lactate threshold (LT) and V O 2max to influence the rate of blood lactate accumulation and therefore, ventilation (V E), CO 2 output (V CO 2 ), and RER peak attained at end exercise (6, 24) . As such, RER peak is a poorly sensitive criterion for V O 2max confirmation.
An alternative exercise testing protocol has been proposed (31) that allows attainment of V O 2max to be detected without the need for secondary criteria. This ramp-incremental (RI) step-exercise (SE) (or RISE) (31) test incorporates a verification phase (19, 23) to determine whether V O 2max has, or has not, been attained during a standard incremental test. Importantly the RISE test provides a within-patient verification by direct comparison of two discrete V O 2peak values generated from two different work rates, meeting the traditional criterion for V O 2max measurement (14) . The outcome is, therefore, patient specific and does not rely on the application of broad cut-off criteria to all participants. This approach has been used successfully in healthy participants [both children (32) and adults (9, 23, 31) ], in children with spina bifida (10) and adolescents with cystic fibrosis (39), but not yet in CHF patients.
We therefore aimed to determine whether the RISE test could provide a more robust method to determine V O 2max in patients with CHF than the traditional secondary criterion (15) . We hypothesized that 1) RER peak would be sensitive to ramp rate in CHF patients, and thus provide a poor criterion for maximal effort and V O 2max detection; and 2) the RISE test would be well tolerated by CHF patients, thus allowing sensitive V O 2max detection independent of ramp rate or secondary criteria.
METHODS
Patients. Twenty-four male and consecutive volunteers with symptomatic but stable CHF (Table 1) , due to left ventricular systolic dysfunction and no recent (Ͻ3 mo) changes in medical therapy, provided written informed consent to participate in this study. All patients had previously undergone a clinically indicated cardiopulmonary exercise test and were approached at the end of the visit unless they were significantly limited by arthritis or severe chronic airways disease. We also excluded a total of 7 patients on the basis of either ongoing ischemia or dysrhythmias (n ϭ 3) or a recent V O2peak Ͼ 20 ml·kg Ϫ1 ·min Ϫ1 (n ϭ 4). The latter criterion was used because patients with a V O2peak Ͼ 20 ml·kg Ϫ1 ·min Ϫ1 generally have significant improvements in prognosis and only mild exercise limitation (20, 25) ; the present study therefore aimed to determine the efficacy of the RISE test in patients with moderate to severe exercise limitation. The investigation was approved by the Leeds West Local Research Ethics Committee, in accordance with the Declaration of Helsinki.
Equipment and measurements. Exercise tests were performed on an electromagnetically braked cycle ergometer (Excalibur Sport, Lode BV, Groningen, The Netherlands). Power output and cadence were recorded from the ergometer via digital data transformation (PowerLab 8/30, ADI Instruments, Chalgrove, UK). A 12-lead electrocardiogram was monitored throughout each test, and heart rate (HR) was measured beat-by-beat from the R-R interval (ECG; Burdick Quest, Cardiac Sciences, Sale, UK). Arterial O2 saturation (SpO2) was measured from the earlobe by pulse oximetry (Biox 3745, Ohmeda, Louisville, KY), and blood pressure by auscultation using a sphygmomanometer. Ratings of perceived exertion (difficulty of breathing and leg discomfort) were recorded by patients on a visual analog scale (0 -100%) during baseline cycling, every 2 min during ramp-incremental exercise, and immediately following volitional exhaustion.
Respired gas was sampled continuously from a mouthpiece at 0.5 ml/s and analyzed at 50 Hz for relative concentrations of N2, O2, and CO 2. Expiratory and inspiratory flows and volumes were measured by a low-dead-space (90 ml), low-resistance (Ͻ0.65 cmH 2O at 8.5 l/s) turbine volume transducer. Gas concentrations and volume signals were digitized every 20 ms and time aligned for breath-by-breath calculation of pulmonary gas exchange (4) (V O2, V CO2, RER) and ventilatory variables (V E; tidal volume, VT; breathing frequency, Bf) (MSX, nSpire Health, Hertford, UK). The system was calibrated before (and verified following) each experiment using precisionanalyzed gas mixtures and a 3-liter syringe (Hans Rudolph, Shawnee, KS). Noninvasive estimation of LT was made independently by three experienced researchers using the V-slope method and corroborated in the profiles of the end-tidal partial pressures of O 2 and CO2, the ventilatory equivalents for V O2 and V CO2, and RER (38) .
Exercise protocols. Following familiarization, patients (n ϭ 24) completed a single visit symptom-limited RISE-95 cycle ergometry test (31) to the limit of tolerance in the format: RI (ramp-incremental; 4 -18 W/min); 5 min recovery (10 W); SE-95 (step-exercise from 10 W to 95% of the peak work rate achieved in the RI). Of this cohort, 18 patients also performed a RISE-95 test with either a fast (10 -30 W/min) or slow (3-8 W/min) RI phase. The fast, medium, and slow ramp tests were performed over consecutive weeks (with 7 days between each visit) in a randomized order and at a similar time of day. The incrementation rate was individually selected for each patient to induce volitional intolerance in approximately 5, 10, and 15 min, respectively. The different ramp durations were determined by initially estimating each patient's V O2peak [as calculated from prediction equations based on sex, age, height, and body mass (26) or from a previously performed clinically indicated exercise test performed in the cardiology clinic], and then by assuming a V O2-to-work rate relationship of 10 ml·W Ϫ1 ·min Ϫ1 (38) . V O2peak estimates from these nomograms were then adjusted downward in line with disease severity and a ramp rate assigned. Each RI and SE phase was terminated when pedal cadence could not be maintained above ϳ50 rpm, and, on one occasion, a test was terminated due to the onset of runs of multifocal ectopic beats. Tests were preceded and followed by at least 4 min of baseline cycling at 10 W. Patients were advised to be postprandial (2-3 h) and refrain from strenuous activity (24 h), caffeine (3 h) and alcohol consumption (48 h) prior to testing.
Data analysis. Breath-by-breath gas exchange and ventilatory responses were edited in the V O2 domain, to exclude occasional breaths that lay outside four SDs of the local mean, resulting from sighs, coughs, swallows, etc. (18) . Peak pulmonary and ventilatory variables from each phase of the RISE-95 test were then determined with the aim of providing a measurement sensitivity of 50 ml/min in the V O2 domain. Sensitivity was identified using a power analysis based on the widest breath-by-breath SD found in all participants to our laboratories over 3 years (150 ml/min) (see also Ref. 18) . A power analysis therefore suggests that a sample size of 12 breaths is sufficient to detect a 50 ml/min difference in V O2, even in patients with the widest breath-by-breath fluctuations. This number of breaths also provides a sufficiently short duration (the average in this study was 19 Ϯ 4 s during both exercise bouts) relative to the different dynamics of the RI and SE phases of the test to allow an appropriate comparison to be made. V O2peak was defined as the greatest V O2 occurring during each Data are means Ϯ SD; n ϭ number of patients. CHF, chronic heart failure; ACE, angiotensin-converting enzyme; DCM, dilated cardiomyopathy; IHD, ischemic heart disease; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
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V o2max in Chronic Heart Failure • Bowen TS et al. exercise phase (RI and SE) and was identified using a 12-breath rolling average. V CO2peak and RERpeak were calculated over the same 12 consecutive breaths as the V O2peak. Peak HR, SpO2, and the ratio of V E/V CO2 at the LT were averaged over ϳ20 s.
Statistical analysis. V O2peak values for RI and SE were compared in each patient by unpaired t-test. Unpaired comparisons were made between the 12-breath clusters at V O2peak in the RI and SE phases because the order of appearance in V O2 values is not paired, even though the comparison is within a patient. V O2max and its individual 95% confidence interval (CI95) (i.e., an individualized measurement sensitivity) was confirmed when the RI and SE V O2peak values did not differ (P Ͼ 0.05). Where differences occurred (P Ͻ 0.05), the greater of the two V O2peak values was reported (with its associated CI95). This analysis resulted in two patient groups being identified, those in whom V O2max was confirmed and those in whom a V O2peak was attained. Following this, therefore, paired t-tests were used for within-group comparisons of variables between RI and SE, while unpaired t-tests were used to compare variables between the two patient groups. Repeated-measures ANOVA was used to compare variables between different ramp rates. Data are presented as means Ϯ SD. All analyses were completed using the Statistical Package for the Social Sciences (SPSS v.16.0, SPSS, Chicago, IL), and significance was accepted at P Ͻ 0.05.
RESULTS
Influence of ramp rate on V O 2peak and RER.
The responses to fast, medium, and slow RI phases are summarized in Table 2 . The V O 2 and RER profile for a representative patient and the group mean are shown in Fig. 1 . The rate (and duration) of the three different RI phases were significantly (P ϭ 0.001) different from each other: fast RI, 19 Ϯ 6 W/min (6 Ϯ 1 min); medium RI, 9 Ϯ 4 W/min (10 Ϯ 1 min); slow RI, 5 Ϯ 1 W/min (15 Ϯ 2 min). There was no effect of ramp rate on V O 2peak (average: 14.4 Ϯ 2.6 ml·kg Ϫ1 ·min Ϫ1 ; P ϭ 0.476 between ramp Data are means Ϯ SD. V O2, pulmonary oxygen uptake; V CO2, pulmonary carbon dioxide output; RER, respiratory exchange ratio; V E, minute ventilation; LT, lactate threshold; HR, heart rate; SpO2, arterial oxygen saturation, Bf, breathing frequency. *P Ͻ 0.01 vs. all other ramp rates; †P Ͻ 0.01 vs. fast ramp rate. rates; n ϭ 18; Table 2 ; Fig. 1, A and C) , but RER peak was correlated with ramp rate such that faster ramp rates resulted in significantly greater RER peak values (P ϭ 0.001; R 2 ϭ 0.49; Table 2 ; Fig. 1, B and D) , averaging 1.21 Ϯ 0.1 (fast RI); 1.15 Ϯ 0.1 (medium RI); and 1.09 Ϯ 0.1 (slow RI). The number of patients who achieved an RER Ն 1.10 [i.e., a common threshold used to confirm maximal effort in CHF and thus V O 2max (2, 3, 22, 29) ] was 18, 14, and 7 for the fast, medium, and slow ramp rates, respectively.
Confirming V O 2max using the RISE-95 test. Patient responses (n ϭ 24) to the RISE-95 test are summarized in Table 3 . In only 1 of the 24 tests was the SE phase not performed at the patient's request. The average duration of the RI and SE phases were 10 Ϯ 2 and 2 Ϯ 1 min, respectively (P ϭ 0.001). Despite the peak work rate in RI being 5% greater than in SE (93 Ϯ 31 vs. 89 Ϯ 30 W; P ϭ 0.001), group V O 2peak was similar between RI and SE: 14.5 Ϯ 3.0 vs. 14.7 Ϯ 3.1 ml·kg Ϫ1 ·min Ϫ1 (P ϭ 0.407). This was also the case when fast or slow ramps were used (n ϭ 18). While these group responses were not different, importantly a within-subject comparison of V O 2peak in RI and SE phases revealed that V O 2max was confirmed in 14 of 24 patients ( ) in 5 of these (Fig. 3) . The CI 95 for V O 2peak estimation averaged 0.9 Ϯ 0.4 ml·kg Ϫ1 ·min Ϫ1 (range 0.6 -1.9 ml·kg Ϫ1 ·min Ϫ1 ). In these 10 patients RER peak in RI was 1.14 Ϯ 0.07 (range 1.05-1.26; Table 3 ). There were no differences in pathological, physiological (including V O 2peak ), or clinical measures between the group of patients in whom a V O 2max was confirmed and those whom attained a V O 2peak . In addition, there was no difference (P ϭ 0.835) in V O 2peak in the RI and SE phases between the two groups (Table 3 ).
In the RISE-95 test the incidence of V O 2max detection was not significantly influenced by ramp rate. Eighteen patients completed the RISE-95 test with a fast, medium, and slow RI phase. In only 2 of the 36 tests was the SE phase contraindicated: one due to the patient's reluctance to continue and the other at the physician's discretion due to the onset of runs of multifocal ectopic beats. The V O 2max criterion was met in 11, 9, and 11 patients in the fast, medium, and slow ramps, respectively, without the need for secondary criteria and consistent with a high precision of the test. Using the traditional criterion for V O 2max detection however [RER peak Ն 1.10 (2, 3, 22, 29 ). Symptoms limiting exercise. During the RISE-95 test patient ratings at peak exercise for leg discomfort (82 Ϯ 13%) were greater (P ϭ 0.002) than those for difficulty of breathing (66 Ϯ 21%). There were no differences between the RI and SE ratings for difficulty of breathing (64 Ϯ 21 vs. 69 Ϯ 23%; P ϭ 0.204) or leg discomfort (80 Ϯ 13 vs. 83 Ϯ 13%; P ϭ 0.595), respectively.
DISCUSSION
The novel findings of this study for an exercise test incorporating ramp-incremental and a verification phase [i.e., a RISE-95 test (31)] were that 1) the test was well tolerated by patients with CHF; 2) the test provided criterion detection of V O 2max with a measurement sensitivity that was individualized for each patient; 3) V O 2max detection was independent of objective and subjective secondary measurements for confirmation of V O 2max attainment; 4) the test provided high precision in V O 2max identification over a range of ramp-incrementation rates; and 5) V O 2max was confirmed in only 60% of all Table 3 . tests by CHF patients, despite group comparisons suggesting V O 2max attainment in all. In addition, these data confirm that RER peak is influenced by ramp rate during an incremental exercise test in CHF patients (6, 24) , and that its use provides a false positive or negative for V O 2max detection in up to ϳ40% of cases. We therefore recommend that the use of RER peak as a measure of good effort (and hence V O 2max corroboration) be viewed with extreme caution. As an alternative, the present data provide evidence to support the use of the RISE-95 test to accurately and reliably determine (or refute) V O 2max along with a measurement sensitivity (CI 95 ) that is specific for each individual. The information provided by the RISE-95 test [which includes the V O 2max criterion together with other prognostic indicators such as V E/V CO 2 and LT (33)] could therefore be beneficial in directing assessment and treatment in CHF patients.
Cardiopulmonary responses to the ramp-incremental (RI) and step-exercise (SE) phases of the RISE-95 test in CHF patients who either confirmed (n ϭ 14) or failed to confirm (n ϭ 10) maximal oxygen uptake (V O 2max )
Influence of ramp rate on RER. The V O 2peak at the limit of tolerance is a powerful diagnostic measure in CHF and provides key information on severity, prognosis, and the need for cardiac transplantation (20) . However V O 2peak is effort dependent, meaning that a low value may not solely reflect the attainment of the physiological limit of V O 2 . Conversely, V O 2max is difficult to determine during standard incremental protocols because of the poor incidence (or sensitivity for detecting) a plateau in the dynamic V O 2 profile (9, 31) . For this reason a range of measurements corroborating maximal effort are suggested (15, 22) , and of these the criterion that RER peak exceeds a specific threshold value is the most common. For CHF patients RER peak values Ͼ 1.00 (12), Ͼ 1.05 (21), or Ն 1.10 (2, 3, 22, 29) have been recommended. However, and in contrast to recommended CHF guidelines (2, 3, 12, 22, 29) , our findings suggest that the RER peak is inappropriate for confirming maximal effort and V O 2max .
This finding is likely due to the dynamics of V CO 2 and its relation with the kinetics of CO 2 storage and production. The CO 2 evolved at the lung preceding and during peak exercise is derived from three sources: 1) metabolically produced CO 2 ; 2) additional CO 2 derived from the buffering of H ϩ associated with the increase in blood and muscle [lactate] ; and 3) compensatory hyperventilation in response to the metabolic acidosis reducing CO 2 stores in the lung and other tissues (40) . The faster ramp rates are suggested to induce a more rapid rate of [lactate] production, which in turn results in a greater rate of CO 2 to be produced at the lung (40), leading to higher values Fig. 2 . Breath-by-breath pulmonary oxygen uptake (V O2) dynamics in two CHF patients in response to the ramp-incremental (RI) step-exercise (SE) at 95% peak RI work rate (i.e., RISE-95) test. In the patients presented, one confirmed maximal oxygen uptake (V O2max; A), while the other did not (V O2peak; B). Our within-patient analysis confirmed V O2max in patients by statistically comparing the highest 12 breaths during exercise in the RI and SE phases, with values of P Ͼ 0.05 confirming V O2max. Dotted lines are presented to highlight the differences in the values of V O2peak between the RI and SE phases. *P Ͻ 0.05. Fig. 3 . Relationship (A) and Bland-Altman plot (ϮSD) of the mean difference (⌬) (B) between the peak pulmonary oxygen uptake (V O2peak) achieved during the ramp-incremental (RI) and step-exercise (SE) (RISE-95) test in CHF patients who did (n ϭ 14; ) or did not (n ϭ 9; OE) confirm maximal oxygen uptake (V O2max). Of note, 1 of the 24 patients elected not to perform the SE bout.
of RER peak . This sensitivity of RER peak to testing protocol is consistent with previous findings in healthy people (6) and CHF patients (24) (although see Ref. 1) , and perhaps helps to explain why the use of RER peak Ն 1.10 led to a false positive or negative for V O 2max detection in ϳ40% of our patients.
Confirming V O 2max within CHF patients. The maximum rate of O 2 delivery and utilization [V O 2max (37) ] is regarded as the gold standard measure of aerobic capacity and integrated neuromuscular-cardiopulmonary functioning (29) . Traditionally, V O 2max has been confirmed by an increase in work rate without an increase in V O 2 , such that a "plateau" in V O 2 is exhibited when approaching the tolerable limit during incremental testing (14) . This feature, however, is rarely discerned in CHF patients using modern ramp-incremental protocols [or indeed in healthy individuals, where plateau incidence is less than ϳ50% (9, 15, 31) ]. For this reason it was recommended (31) that RI exercise be followed by a verification phase (9, 19, 23) using a step increase to a work rate different from the peak work rate previously attained, thereby satisfying the plateau criterion for V O 2max where two different work rates are terminated at the same V O 2 (14) . This approach has been shown to be effective in a range of healthy and patient groups (9, 10, 23, 31, 32, 39) , but this study is the first demonstrating its efficacy in CHF patients.
An important addition of the present study is the application of a novel criterion to detect V O 2max and the associated CI 95 for each individual. Previous studies using a verification phase to determine V O 2max have typically focused on comparing group means; however, the clinical utility of this exercise test is its application to the individual rather than the group (27) . Therefore the demonstration that V O 2max may be detected using a RISE-95 test within patients to a patient-specific confidence limit (and without the need for corroborating criteria) provides improved accuracy and precision to current techniques. Our findings are also consistent with the notion that peak exercise testing is safe and well tolerated by CHF patients (28) , and even suggests repeated peak efforts may be safely performed after only a few minutes of active recovery. No adverse events occurred during 60 of the RISE-95 tests administered and the completion rate was high: the SE phase was completed in 57 of the 60 tests administered.
In the present study we defined V O 2peak attained in each phase of the RISE-95 test as the highest mean V O 2 value achieved in 12 consecutive breaths during exercise. It is well recognized, especially in CHF patients (8) , that V O 2 may increase after exercise cessation. Although the actual mechanisms for this increase are not well defined (and may vary between individuals), there is a series of events that may contribute to the increase in V O 2 after cessation in CHF. An acute increase in stroke volume during active recovery from peak RI [consistent with the observed increase in O 2 pulse in some CHF patients (38) ] may occur in CHF patients due to an abrupt reduction in thoracic pressure and end-expiratory lung volume, together with a relative maintenance of peak HR and muscle pump in active recovery. This can result in an acute increase in cardiac output (36) and therefore in V O 2 measured across the lung, which may be exacerbated by reduced lung O 2 stores (from a reduced end-expiratory lung volume) when V O 2 is measured at the mouth (41) . In addition, the long limb-tolung transit time at peak RI, associated with low absolute cardiac output in CHF (35) , can result in the arteriovenous O 2 concentration difference across the lung continuing to rise for ϳ15-20 s after exercise cessation, despite the dramatic reduction in power output. This effect is thought to be less at a greater absolute V O 2 and cardiac output values (i.e., in healthy or endurance-trained subjects) where the rate of rise in arteriovenous O 2 concentration difference across the legs at the end of the RI phase is less pronounced than in CHF (17, 35) . Consistent with this we found a modest 40 Ϯ 32 ml/min increase in pulmonary V O 2 in ϳ30% of our patients in the present study. However, in line with previous suggestions (7) we reported the V O 2peak and V O 2max values as those achieved during the exercise (rather than in recovery) as this reflects the functional physiological limitation of the task being performed.
An interesting finding of the present investigation was that 5 of 24 patients (ϳ20%) achieved a statistically greater V O 2peak in the SE phase of the RISE-95 test (Fig. 3) . This is very rarely seen in healthy subjects (Refs. 9, 31; unpublished observations from our laboratory suggest an incidence of ϳ3%) and suggests CHF patients may have a cardiac and/or metabolic reserve (11, 16) , with the alleviation of some limit to cardiac output or muscle O 2 extraction between RI and SE allowing V O 2peak to be greater in SE. The mechanism underlying the increase in V O 2peak in these 5 patients is unclear, as no clinical or physiological differences were detected. An increase in muscle recruitment (16) between RI and SE seems unlikely considering the exercise modality was identical and work rate was 5% lower during the SE bout. Moreover, increased cardiac output between bouts also seems unlikely considering longterm exercise training fails to significantly improve hemodynamic measurements in CHF patients (34) . It is possible that patients' symptoms may have been attenuated between exercise phases allowing an increase in V O 2peak ; however, symptoms at peak exercise were also similar between bouts. Therefore, the increase in V O 2peak may relate to the residual effects of the previous exercise bout. In CHF patients (5) and healthy older adults (13), warm-up exercise can speed V O 2 kinetics while also increasing microvascular O 2 delivery and intramuscular aerobic enzyme activity. Whether these mechanisms can increase the V O 2peak in CHF remains to be determined. Whatever the etiology of this mechanism(s), however, targeting it could provide a beneficial avenue for therapeutic interventions to increase aerobic capacity and thus benefit the activities of daily living in CHF patients.
Clinical implications. The present data suggest that RER peak as a measure of maximal effort in cardiopulmonary exercise testing be abandoned, and the RISE-95 test is recommended for V O 2max confirmation. This may have important consequences for current clinical guidelines. For example, out of all tests the increase in V O 2peak between RI and SE phases led some patients (17%) to acutely increase Weber classification scores and other patients (38%) to cross thresholds of cardiac transplantation listing, either as an accepted indication (n ϭ 2; Յ10 ml·kg Ϫ1 ·min Ϫ1 ) or a probable indication (n ϭ 4 for Յ14 ml·kg Ϫ1 ·min Ϫ1 ; and n ϭ 3 for Յ12 ml·kg Ϫ1 ·min Ϫ1 in presence of ␤-blocker therapy) (20, 21) . The significance of these findings cannot be directly assessed in this small cohort study, but there is a clear implication that patient stratification and treatment decisions may be affected by "underestimation" of V O 2max . The practical application and statistical analysis for V O 2max confirmation using the RISE test is simple and therefore could be easily incorporated into computational algo-456 V o2max in Chronic Heart Failure • Bowen TS et al. rithms in commercial "metabolic cart" software to provide an objective assessment of attainment (or not) of V O 2max . This would provide an increased accuracy and precision for patient stratification or identification of patients with poor motivation or a poor quality test for other reasons (whose exercise test outcomes could then be interpreted with the appropriate caveat). The RISE-95 test could also increase cost effectiveness of treatment strategies in CHF by reducing the incidence of misdirected therapeutic consequences that are, in part, due to an underestimation of maximal responses in cardiopulmonary exercise testing.
Whether V O 2max detection by the RISE-95 test could provide a stronger prognostic or diagnostic tool than V O 2peak (20) , or other prognostic markers (33) , is currently unclear. For example, a recent comprehensive review suggests that V E/V CO 2 (a noninvasive proxy for abnormalities in pulmonary ventilation-toperfusion inequalities) provides a stronger prognostic index than V O 2peak (33) . Whether the V O 2peak /V O 2max value obtained in the RISE-95 test would increase the prognostic value of V O 2 in this regard, however, remains to be determined, because previous tests may have underestimated the V O 2max in a significant proportion of cases. Considering all tests in the present study, this "underestimation" exceeded 0.6 ml·min Ϫ1 ·kg Ϫ1 in ϳ60% of patients, a value that was associated with an 11% reduction in all-cause mortality and hospitalizations in a recent large multicenter clinical trial of exercise training in CHF (28) . Moreover, seven patients (ϳ30%) in the present study increased V O 2peak between RI and SE by more than the generally accepted minimal important clinical difference of 10% (28) . Nevertheless, as both V E/V CO 2 (determined submaximally) and V O 2max are independently and objectively determined in the RISE-95 test, a prognostic test that incorporates both measurements (and possibly others, e.g., estimated LT) may provide the strongest predictive power offered by cardiopulmonary exercise testing (33) . Our findings also suggest that the RISE-95 test may have important implications for current equations predicting patients' V O 2peak (26, 38) . However, these data were collected from a relatively small and exclusively male patient group, and a wider study with long-term follow-up is needed to clarify any predictive or prognostic value of the test and to extend the present findings to the wider CHF population.
Conclusions. The present study has found that ramp-incrementation rate significantly influences the RER peak during peak exercise testing in patients with CHF. These data suggest, therefore, that the use of RER peak as a measure of good effort (and hence V O 2max corroboration) be abandoned. In contrast, the present data provide evidence to support the use of the RISE-95 test (31) . This protocol was well tolerated by CHF patients, able to detect V O 2max with a measurement sensitivity (CI 95 ) specific for each patient, independent of additional objective or subjective secondary measurements used to confirm V O 2max , and provided high precision over a range of incrementation rates. Together these data suggest that the RISE-95 test should be included in standard clinical exercise testing procedures.
